Authors: NUR SOYER, RIDVAN ALİ, MEHMET TURGUT, İBRAHİM CELALETTİN HAZNEDAROĞLU, ASU FERGÜN YILMAZ, İSMET AYDOĞDU, ALİ PİR, VOLKAN KARAKUŞ, GÖKHAN ÖZGÜR, CEM KİS, FUNDA CERAN, GÜL İLHAN, MELDA ÖZKAN, MÜZEYYEN ASLANER, İDRİS İNCE, İRFAN YAVAŞOĞLU, FÜSUN GEDİZ, MEHMET SÖNMEZ, BİROL GÜVENÇ, GÜLSÜM ÖZET, EMİN KAYA, FİLİZ VURAL, FAHRİ ŞAHİN, MAHMUT TÖBÜ, İSABEL RAİKA DURUSOY ONMUŞ, GÜRAY SAYDAM
Abstract: Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28-87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10-40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 ± 46.79 mm versus 199.49 ± 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1-55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.
Keywords: Myelofibrosis, treatment, survival, ruxolitinib, adverse events
Full Text: PDF